U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H19ClF2N4O4
Molecular Weight 512.8934
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-777607

SMILES

CCOc1ccn(-c2ccc(cc2)F)c(=O)c1C(=Nc3ccc(c(c3)F)Oc4cc[nH]c(=N)c4Cl)O

InChI

InChIKey=VNBRGSXVFBYQNN-UHFFFAOYSA-N
InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)

HIDE SMILES / InChI

Molecular Formula C25H19ClF2N4O4
Molecular Weight 512.8934
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/20515943 | https://www.ncbi.nlm.nih.gov/pubmed/26848524 | https://www.ncbi.nlm.nih.gov/pubmed/19260711

BMS 777607 is a substituted 2-aminopyridine shown to inhibit the RON and cMet receptor tyrosine kinases, for the treatment of solid tumors. BMS 777607 demonstrated ligand stimulated and constitutive Met phosphorylation, and inhibition of tumor cell proliferation, in preclinical studies. Preclinical data indicated that BMS 777607 inhibited RON, blocking the conversion of micrometastases to overt metastases by boosting antitumor immunity. Bristol-Myers Squibb conducted a phase I/II trial of BMS 777607 for the treatment of advanced solid tumors in Australia. As at December 2016, no recent reports of development had been identified for preclinical development in Cancer in the USA.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.89999999999999991 nM [IC50]
1.80000000000000004 nM [IC50]
Conditions
PubMed

PubMed

TitleDatePubMed
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
2009 Mar 12
BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
2010 Jun
Patents

Sample Use Guides

U118MG and SF126 cells were implanted stereotactically into the brains of CD1NuNu mice. In the more aggressive tumor SF126 model, treatment was started at day 3 after implantation while treatment in the U118MG model was started on day 7 after implantation. In both models, BMS-777607 treatment (30 or 100 mg/kg, i.p. 2x/day) resulted in a significant decrease of intracranial tumor growth on day 14 after implantation.
Route of Administration: Intraperitoneal
Human high-grade glioma cells U118MG and SF126 glioma cells were treated with BMS-777607 at different concentrations (1.56 mkM–50 mkM). Culture medium was replaced or exchanged after 24, 48 and 72 hours. The exposure of U118MG and SF126 glioma cells with 12.5 μM BMS-777607 resulted in significantly reduced cell numbers in MTT assay after 24 hours of treatment.
Substance Class Chemical
Created
by admin
on Sat Jun 26 01:31:24 UTC 2021
Edited
by admin
on Sat Jun 26 01:31:24 UTC 2021
Record UNII
A3MMS6HDO1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-777607
Code English
ASLAN-002
Code English
3-PYRIDINECARBOXAMIDE, N-(4-((2-AMINO-3-CHLORO-4-PYRIDINYL)OXY)-3-FLUOROPHENYL)-4-ETHOXY-1-(4-FLUOROPHENYL)-1,2-DIHYDRO-2-OXO-
Systematic Name English
ASLAN002
Code English
N-(4-((2-AMINO-3-CHLOROPYRIDIN-4-YL)OXY)-3-FLUOROPHENYL)-4-ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE
Systematic Name English
Code System Code Type Description
CAS
1025720-94-8
Created by admin on Sat Jun 26 01:31:24 UTC 2021 , Edited by admin on Sat Jun 26 01:31:24 UTC 2021
PRIMARY
FDA UNII
A3MMS6HDO1
Created by admin on Sat Jun 26 01:31:24 UTC 2021 , Edited by admin on Sat Jun 26 01:31:24 UTC 2021
PRIMARY
DRUG BANK
DB12064
Created by admin on Sat Jun 26 01:31:24 UTC 2021 , Edited by admin on Sat Jun 26 01:31:24 UTC 2021
PRIMARY
EPA CompTox
1025720-94-8
Created by admin on Sat Jun 26 01:31:24 UTC 2021 , Edited by admin on Sat Jun 26 01:31:24 UTC 2021
PRIMARY
ChEMBL
CHEMBL460702
Created by admin on Sat Jun 26 01:31:24 UTC 2021 , Edited by admin on Sat Jun 26 01:31:24 UTC 2021
PRIMARY
PUBCHEM
24794418
Created by admin on Sat Jun 26 01:31:24 UTC 2021 , Edited by admin on Sat Jun 26 01:31:24 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY